J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more
TL;DR: The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.
Journal ArticleDOI
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Nancie M. Archin,Abigail L. Liberty,Angela D. M. Kashuba,Shailesh K. Choudhary,Joann D. Kuruc,Amanda M. Crooks,Daniel C. Parker,Elizabeth M. Anderson,Mary F. Kearney,Matthew C. Strain,Douglas D. Richman,Michael G. Hudgens,Ronald J. Bosch,John M. Coffin,Joseph J. Eron,Daria J. Hazuda,David M. Margolis +16 more
TL;DR: It is demonstrated that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.
Antiretroviral Treatment of Adult HIV Infection
Scott M. Hammer,Joseph J. Eron,Peter Reiss,Robert T. Schooley,Melanie A. Thompson,Sharon Walmsley,Pedro Cahn,Margaret A. Fischl,José M. Gatell,Martin S. Hirsch,Donna M. Jacobsen,Julio S. G. Montaner,Douglas D. Richman,Patrick Yeni,Paul A. Volberding +14 more
TL;DR: This report provides guidelines in key areas of antiretroviral management: when toinitiatetherapy, choice of initialimens, patient monitoring, and how best to approach treatment options, including optimal use of recently approved drugs in treatment-experienced patients.
Journal ArticleDOI
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Jacob Lalezari,Keith Henry,Mary O'Hearn,Julio S. G. Montaner,Peter J. Piliero,Benoit Trottier,Sharon Walmsley,Calvin J. Cohen,Daniel R. Kuritzkes,Joseph J. Eron,Jain Chung,Ralph DeMasi,Lucille Donatacci,Claude Drobnes,John Delehanty,Miklos Salgo +15 more
TL;DR: The addition of enfuvirtide to an optimized antiretroviral and immunologic benefit through 24 weeks in patients who had previously received multiple antireTroviral drugs and had multidrug-resistant HIV-1 infection.
Journal ArticleDOI
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1
Myron S. Cohen,Irving F. Hoffman,Rachel A. Royce,Peter N. Kazembe,John R. Dyer,Celine Costello Daly,Dick Zimba,Pietro Vernazza,Martin Maida,Susan A. Fiscus,Joseph J. Eron +10 more
TL;DR: HIV-1-control programmes, which include detection and treatment of STDs in patients already infected with HIV-1, may help to curb the epidemic and targeting of gonococcal urethritis may be a particularly effective strategy.